Microsoft founder gives $300m more for brain research institute
This article was originally published in Scrip
Microsoft co-founder Paul G. Allen gave $300 million to the eponymous Allen Institute for Brain Science to expand scientific programmes at the Seattle, Washington non-profit organization he started with $100 million in 2003 to foster brain research that would fuel discoveries in the broader scientific community.
You may also be interested in...
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.